// App-Quantinova.ai

P52.03 : Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100

Researchers

Presenter

  • S. Ramalingam

Principal Investigators

  • F. Skoulidis

  • R. Govindan

  • V. Velcheti

  • B. Li

  • D. Kim

  • M. Schuler

  • M. Vincent

  • F. Wilson

  • J. Park

  • J. Gutierrez

  • S. Jones

  • J. Wolf

Medical Centers

  • Amgen Inc, Thousand Oaks, CA

  • Seoul National University Hospital, Seoul, Korea

  • Emory University, Atlanta, GA

  • Internal Medicine, Section of Allergy and Clinical Immunology, Yale University School of Medicine, New Haven, CT

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • West German Cancer Center, University Hospital, Essen, Germany

  • Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/NY/US

  • London Health Sciences Centre London Ontario Canada

  • Radmd, Conshohocken/US

  • NYU Langone Health, New York, NY

  • Alvin J Siteman Cancer Center at Washington University School of Medicine, St. Louis, MO

  • Thoracic / Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston/TX/US

  • Gustave Roussy, Villejuif France and Paris Sud University, Paris/FR

  • Roswell Park Cancer Institute, Buffalo, NY

Locations

  • United States

  • Germany

  • United Kingdom

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Non Small Cell Lung cancer

Biomarkers

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT04185883

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved